(Press-News.org) Mountain View, CA – June 5, 2014 – Amunix Operating Inc. said today it is presenting unpublished data from its XTEN half-life extension technology development programs during two sessions this week at IBC's 9th Annual Next Generation Protein Therapeutics Summit in San Francisco, CA. Amunix is a biotechnology company developing hydrophilic, unstructured polypeptides which can be recombinantly fused or chemically conjugated to other peptides, proteins and small molecules.
Vladimir N. Podust, PhD, Director of Analytical Chemistry, Amunix Operating Inc., will present "Extension of in vivo Half-Life of Biologically Active Molecules via Chemical Conjugation to XTEN Protein Polymer" today at 11 am during the section titled "Alternative Scaffolds and Delivery Strategies."
XTEN (unstructured biodegradable polypeptides) have been used to extend the half-life of genetically fused therapeutic proteins and peptides. To expand the applications of XTEN technology to half-life extension of other classes of molecules, XTEN protein polymers and methods for chemical XTENylation were developed. Monovalent, multivalent and bispecific XTEN conjugates with various payloads have been synthesized and tested for their biological activities.
The presentation will show an efficient method of synthesis of targeted XTEN-drug conjugates, exemplified by folate as a targeting moiety and DM1 as a chemical toxin. The modular synthetic approach allows investigation of the effects of valency and polymer length, as well as the nature of the toxic payload to select the most potent product format for each indication.
Volker Schellenberger, PhD, Amunix President and Chief Executive Officer, will present "XTEN – A Biodegradable Alternative to PEG Enabling Biopharmaceuticals with Precisely Controlled Structure and Valency" tomorrow, June 6 at 9:15 am during the section titled "Alternatives to PEG for Plasma Half-Life Extension."
Amunix has developed XTEN, a protein-based polymer that mimics the biophysical properties of PEG. XTEN is easily metabolized, thereby eliminating the risk of tissue accumulation. Single or multiple payloads can be conjugated or genetically fused to XTEN which allows the generation of monospecific, bispecific, as well as multivalent biopharmaceuticals.
This presentation will focus on the ability to customize XTEN for each application to enable discovery of long-acting biologics with best-in-class product attributes. Amunix's technology allows one to include multiple XTEN polymers into a single product while maintaining precise positional control of each insertion site. Each insertion site and the length of inserted XTEN can be optimized to maintain or enhance biological activity while achieving increased duration of action of the resulting product. Examples of XTENylated biologics with class-leading duration of action will be shown.
INFORMATION:
About Amunix
Amunix Operating Inc., a biotechnology company headquartered in Mountain View, CA, has developed a novel half-life extension technology based on XTEN; hydrophilic, unstructured polypeptides which can be recombinantly fused or chemically conjugated to other peptides, proteins and small molecules. Through this proprietary XTEN technology, the company creates and develops novel versions of clinically-proven pharmaceutical products that may offer better efficacy, safety and dosing frequency by extension of the half-life. Two XTEN products – Exenatide-XTEN (VRS-859) and hGH-XTEN (VRS-317) – have completed Phase 1 studies through Amunix partners Diartis and Versartis, respectively. Versartis is currently conducting a Phase 2a study with VRS-317 in pediatric growth hormone deficient patients. In addition, through its partnership with Biogen Idec, Amunix is developing Factor VIII and is working with Janssen Biotech, Inc. and its affiliates to apply the XTEN half-life extension technology with protein and/or peptide therapeutics selected by Janssen. Amunix has several other undisclosed partners in various therapeutic areas. Founded in 2006, Amunix is a profitable, independent biotechnology company with no external investors. Amunix is actively seeking partnerships for application of its XTEN technology. For additional information about the company, please visit http://www.amunix.com.
Amunix Media Contact:
Debra Catz Bannister
media@amunix.com
530 676-7373
Amunix presents XTEN half-life extension technology at Next Generation Protein Therapeutics Summit
2014-06-05
ELSE PRESS RELEASES FROM THIS DATE:
New EU reforms fail European wildlife
2014-06-05
Despite political proclamation of increased environmental focus, experts argue that the European Union's recent agricultural reforms are far too weak to have any positive impact on the continent's shrinking farmland biodiversity, and call on member states to take action.
About half of all farmland and at least 88% of EU farmers are exempt from Ecological Focus Areas, the main "greening measure" that could help wildlife on farmland.
Meeting EU's own biodiversity targets for 2020 now relies on initiatives from member states.
Experts from leading organisations offer ...
What's in the sheep genome? Wool see
2014-06-05
After eight years of work, researchers have completed the first sequencing of the entire sheep genome.
Scientists from CSIRO led an international research team to complete the sequencing, which could lead to more effective breeding strategies and new approaches to the management of sheep in Australia and around the world.
With about 70m head of sheep in Australia and 1bn globally, the sequencing of the genome could have a massive impact for the rural economy given that sheep are a major source of meat, milk and wool products.
"We investigated the completed genome to ...
Sleep after learning strengthens connections between brain cells and enhances memory
2014-06-05
June 5, 2014 -- In study published today in Science, researchers at NYU Langone Medical Center show for the first time that sleep after learning encourages the growth of dendritic spines, the tiny protrusions from brain cells that connect to other brain cells and facilitate the passage of information across synapses, the junctions at which brain cells meet. Moreover, the activity of brain cells during deep sleep, or slow-wave sleep, after learning is critical for such growth.
The findings, in mice, provide important physical evidence in support of the hypothesis that ...
Scientists crack sheep genome, shining spotlight on rumen evolution and lipid metabolism
2014-06-05
Shenzhen, June 5, 2014--- The latest study, led by scientists from Kunming Institute of Zoology, Chinese Academy of Sciences, BGI and other institutes, presents a high-quality sheep genome and reveals genomic and transcriptomic events that may be associated with rumen evolution and lipid metabolism that have relevance to both diet and wool. The work was published online today in Science.
Sheep are ruminants with a complex, 4-compartmented "stomach", the largest compartment is the rumen, which is thought to have evolved around 35-40 million years ago, and has the ability ...
Gene study shows how sheep first separated from goats
2014-06-05
Scientists have cracked the genetic code of sheep to reveal how they became a distinct species from goats around four million years ago.
The study is the first to pinpoint the genetic differences that make sheep different from other animals.
The findings could aid the development of DNA testing to speed-up selective breeding programmes, helping farmers to improve their stocks.
The research identifies the genes that give sheep their fleece and uncovers features of their digestive system, which makes them so well-suited to a diet of low quality grass and other plants.
It ...
Brain circuit problem likely sets stage for the 'voices' that are symptom of schizophrenia
2014-06-05
(MEMPHIS, Tenn. – June 5, 2014) St. Jude Children's Research Hospital scientists have identified problems in a connection between brain structures that may predispose individuals to hearing the "voices" that are a common symptom of schizophrenia. The work appears in the June 6 issue of the journal Science.
Researchers linked the problem to a gene deletion. This leads to changes in brain chemistry that reduce the flow of information between two brain structures involved in processing auditory information.
The research marks the first time that a specific circuit in the ...
Research could lead to new cancer assay, aid both dogs and humans
2014-06-05
CORVALLIS, Ore. – Veterinary researchers at Oregon State University have identified a unique group of proteins that indicate the presence of transitional cell carcinoma – the most common cause of bladder cancer – and may lead to a new assay which could better diagnose this disease in both dogs and humans.
Bladder cancer is particularly common in some dog breeds, such as collies, sheepdogs and terriers, but is rarely diagnosed in animals before it has spread significantly. Some assays exist to detect it in humans, but they often have a high-number of false-positive identifications.
An ...
New clues to why older women are more vulnerable to breast cancer
2014-06-05
Scientists from the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have gained more insights into why older women are more susceptible to breast cancer. They found that as women age, the cells responsible for maintaining healthy breast tissue stop responding to their immediate surroundings, including mechanical cues that should prompt them to suppress nearby tumors.
Their work sheds light on how aging alters cellular and molecular functions, and how these changes contribute to the prevalence of breast cancer in older women. The disease is ...
MAD: Scientists shed light on braking mechanisms in cellular signaling
2014-06-05
Stanford, CA— A team of researchers studying a flowering plant has zeroed in on the way cells manage external signals about prevailing conditions, a capability that is essential for cells to survive in a fluctuating environment.
Researchers at UC Berkeley, the Plant Gene Expression Center, UC San Francisco, and the Carnegie Institution for Science identified a novel mechanism by which the strength of such an external signal is reduced, or attenuated. Their work focuses on the tiny mustard plant Arabidopsis, which is frequently used by scientists as an experimental model. ...
Exploring a legal and ethical gray area for people with dementia
2014-06-05
(Garrison, NY) Many of the legal and ethical options for refusing unwanted interventions are not available to people with dementia because they lack decision-making capacity. But one way for these people to ensure that they do not live for years with severe dementia is to use an advance directive to instruct caregivers to stop giving them food and water by mouth. This is an ethical and legal gray area explored in commentaries and a case study in the Hastings Center Report.
People with decision-making capacity have the legal right to refuse treatment of any kind and to ...